Concomitant p75 and TrkA binding protects cells from apoptotic death
| Treatment added to SFM cultures | PC12 (TrkA+ p75+) | 4-3.6 (TrkA+ p75+) | |
|---|---|---|---|
| 1 | Mouse IgG | 0 ± 1.3 | 0 ± 1.5 |
| 2 | 1 nm NGF | 100 ± 6.5 | 100 ± 4.8 |
| 3 | 5 pm NGF | 28 ± 8.4 | 48 ± 3.5 |
| 4 | MC192 10 nm | 2 ± 1.5 | 1 ± 4.1 |
| 5 | MC192 1 nm | 6 ± 2.72-a | 6 ± 3.52-a |
| 6 | MC192 0.1 nm | 1 ± 2.0 | 1 ± 4.2 |
| 7 | 5 pmNGF + MC192 10 nm | 49 ± 3.3 | 85 ± 6.5 |
| 8 | 5 pm NGF + MC192 1.0 nm | 86 ± 7.4 | 108 ± 5.6 |
| 9 | 5 pm NGF + MC192 0.1 nm | 26 ± 5.1 | 55 ± 4.5 |
Assays were performed as described in Table 1 legend. mAb MC192 synergizes with suboptimal (5 pm) NGF in protecting PC12 and 4-3.6 cells from apoptotic death in SFM (lanes 7 and 8).
↵F2-a The small increase in survival induced by mAb MC192 is statistically significant.